A placebo-controlled, double-blind study evaluating the effect of orally administered polyunsaturated fatty acids on the oclacitinib dose for atopic dogs.

Published in: Veterinary dermatology (2024)

Oral supplementation of PUFA allowed dose reduction of oclacitinib and improved PVAS, QoL, QoC and GA. The use of PUFA is recommended and was safe in the atopic study dogs receiving oclacitinib.

Keyphrases

double blind
placebo controlled
clinical trial
randomized controlled trial
study protocol
squamous cell carcinoma
pet ct
phase iii